Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.
El-Sayed M, Elserafy M, El Raziky M, Elakel W, Saad Y, Fayad T, Korany M, Mehrez M, Salama R, Mahrous M, Zaki A, Hassany M, Ammar I, Elsaeed K, Elshazly Y, Doss W.
El-Sayed M, et al.
Arab J Gastroenterol. 2023 Feb;24(1):29-33. doi: 10.1016/j.ajg.2022.10.001. Epub 2023 Feb 20.
Arab J Gastroenterol. 2023.
PMID: 36813580